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ORIGINAL ARTICLE

Association of anticoagulation dose and survival in hospitalized
COVID-19 patients: A retrospective propensity score-weighted
analysis
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Abstract
Background: Hypercoagulability may contribute to COVID-19 pathogenicity. The role
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of anticoagulation (AC) at therapeutic (tAC) or prophylactic doses (pAC) is unclear.
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patients.
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Results: A total of 3480 patients were included (mean age, 64.5 years [17.0]; 51.5%
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(ICU) stay. 60.9% received pAC (n = 2121), 28.7% received ≥3 days of tAC (n = 998),
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Objectives: We evaluated the impact on survival of different AC doses in COVID-19
Methods: Retrospective, multi-center cohort study of consecutive COVID-19 patients hospitalized between March 13 and May 5, 2020.
female; 52.1% black and 40.6% white). 18.5% (n = 642) required intensive care unit
and 10.4% (n = 361) received no AC. Propensity score (PS) weighted Kaplan-Meier
plot demonstrated different 25-day survival probability in the tAC and pAC groups
(57.5% vs 50.7%). In a PS–weighted multivariate proportional hazards model, AC was
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associated with reduced risk of death at prophylactic (hazard ratio [HR] 0.35 [95%
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0.23]) compared to no AC. Major bleeding occurred more frequently in tAC patients
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confidence interval {CI} 0.22-0.54]) and therapeutic doses (HR 0.14 [95% CI 0.05(81 [8.1%]) compared to no AC (20 [5.5%]) or pAC (46 [2.2%]) subjects.
Conclusions: Higher doses of AC were associated with lower mortality in hospitalized
COVID-19 patients. Prospective evaluation of efficacy and risk of AC in COVID-19
is warranted.
KEYWORDS

anticoagulation, COVID-19, heparin, novel coronavirus

1 | I NTRO D U C TI O N

caused by the novel pathogen designated severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). Studies have reported co-

Hypercoagulability has emerged as an important component in

agulation abnormalities such as elevated D-dimer and fibrinogen in

the pathogenesis of severe coronavirus disease 2019 (COVID-19)

conjunction with low anti-thrombin levels,1 evidence of endothelial

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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dysfunction, 2 as well as a markedly abnormal coagulation profile
on thromboelastography suggestive of hypercoagulability in the
context of severe systemic inflammation.3,4 Furthermore, marked
elevations in D-dimer level and markers of endothelial dysfunction
(von Willebrand factor antigen, soluble thrombomodulin) have been
correlated with worse outcomes. 2,5,6 One case series of critically ill
COVID-19 patients reported a high incidence of thrombotic complications (31%)

7

and numerous autopsy case series have described

pulmonary and other visceral microthromboses suggesting that coagulation abnormalities are not simply an epiphenomenon but are
likely major pathogenic components.8-11
A small number of retrospective studies have observed that
thromboprophylactic-dose anticoagulation is associated with improved outcomes in patients with COVID-19, but a growing body

Novelty Statements
1. We retrospectively compared survival of patients
treated with different anticoagulation doses in a large
cohort.
2. Higher doses of anticoagulation were associated with
prolonged survival, especially in critically ill patients, but
this larger effect size came at the cost of excess nondisabling bleeding.
3. Anticoagulation may be considered in the treatment of
hospitalized COVID-19 patients, but prospective studies are required to further assess the benefit and bleeding risk.

of evidence suggests a possible advantage with using more intense
regimens. Our group found a dose- and duration-dependent delay in
death in a cohort of 127 deceased patients with severe COVID-19.12

tested positive for SARS-CoV-2 prior to the admission date or after

Others have also explored the effect of AC in a large cohort of hos-

the third day of hospitalization were excluded. Data were obtained

pitalized COVID-19 patients and found superior outcomes for those

automatically from electronic records. The study was approved by

treated with tAC, but the comparison group consisted of patients

the Institutional Review Board (IRB # 2020-125). In the absence of

who either received pAC or no AC, and no conclusions could be

evidence-based criteria for initiating AC in COVID-19 patients, our

13

reached regarding optimal dosing.

Notably, in critically ill patients,

institution published internal recommendations for the use of tAC

a significant association with improved survival in subjects treated

for disease requiring mechanical ventilation, worsening kidney fail-

with tAC compared to pAC was observed.14 A subsequent analysis

ure and/or a D-dimer >6-fold the upper limit of normal (>3000 ng/

of the same cohort again found superior outcomes with the use of

mL fibrinogen-equivalent-units), but tAC could also be initiated at

AC, but a direct comparison between tAC and pAC failed to show a

the discretion of the clinician and as salvage therapy. The recom-

significant difference.11

mended duration of tAC was 5 days based on expert consensus, but

There is a lack of large observational data examining outcomes
among patients with COVID-19 receiving tAC compared with pAC

treatment could be extended in the presence of a clear indication or
by clinician choice.

or no AC and available results are conflicting. We hypothesized

Therapeutic anticoagulation was defined as a minimum 3-day

that tAC and pAC may be associated with improved outcomes in

course of either: (a) intravenous unfractionated heparin (UFH)

a dose-dependent manner relative to no AC among hospitalized

with at least one documented activated partial thromboplas-

patients with COVID-19. We further hypothesized that these as-

tin time in the anticoagulation range (≥45 seconds); (b) subcuta-

sociations may be strongest among critically ill patients receiving

neous enoxaparin at doses of 1 mg/kg twice daily or 1.5 mg/kg

mechanical ventilation. We also sought to determine the risk of

once daily (while allowing for dose adjustment based on creatinine

major bleeding. Accordingly, we performed an observational cohort

clearance); (c) intravenous argatroban infusion; (d) subcutaneous

study in the largest hospital network in Southeast Michigan, USA,

fondaparinux at doses of 5-10 mg once daily (weight-based dos-

examining survival relative to anticoagulation dose in hospitalized

ing); or (e) oral anticoagulants (warfarin, apixaban, rivaroxaban,

patients with COVID-19.

dabigatran) prescribed prior to and continued throughout hospitalization. Prophylactic anticoagulation (pAC) was defined as one

2 | M E TH O DS
2.1 | Study design

of the following administrations on most days of hospitalization:
1) subcutaneous injection of UFH at doses of 5000 units twice or
three times daily; subcutaneous enoxaparin injection at doses of
30-40 mg once daily; or 3) subcutaneous fondaparinux at a dose
of 2.5 mg once daily. Patients who received therapeutic anticoag-

We conducted a retrospective analysis of a large cohort of consecu-

ulation for less than 3 days were also included in the pAC group.

tive COVID-19 patients hospitalized within the largest academic

Because many patients transitioned between anticoagulants de-

healthcare system comprised of eight hospitals located in Southeast

pending on ability to ingest oral medication and the safety profile

Michigan, USA. Patients aged 18 years or older who tested positive

of the drug, the specific anticoagulant agent administered in the

for SARS-CoV-2 on nucleic amplification testing of nasopharyngeal

most doses was considered the primary anticoagulant for a given

secretions between March 13, 2020, and May 5, 2020, were ret-

patient. Immunosuppressive corticosteroid therapy was defined

rospectively identified from electronic medical records. To ensure

as at least one dose of greater than 15 mg methylprednisolone

the main reason for hospitalization was COVID-19, subjects who had

or equivalent dose of other corticosteroid. For the purposes of

|
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analysis, intensive care unit (ICU) stay was defined as need for me-

chronic lung disease). The balance of the propensity scores was

chanical ventilation to maintain adequate oxygenation.

examined using the standardized effect size. Schoenfeld, devi-

Major bleeding was defined as either: (a) transfusion of five or

ance residuals, and Grambsch-Therneau test evaluated the fit of

more units of packed red blood cells within 48 hours, regardless of

the multivariate Cox model and the proportionality of hazards as-

hemoglobin level; (b) hemoglobin <7 g/dL and any red blood cell

sumptions, respectively. PS-weighted Kaplan-Meier curves were

transfusion; (c) a diagnosis code for major bleeding during the hos-

plotted to compare in-hospital mortality between groups and

pitalization (gastrointestinal hemorrhage, intracranial hemorrhage

groups were compared using the log-rank test. A Cox Proportional

etc); or (d) evidence of intracranial hemorrhage obtained from re-

Hazard model with propensity score (PS) weights was fitted to the

ports of head computed tomography scans. The higher cutoff of five

data to assess the effect of covariates on mortality. Univariate

units of packed red blood cells within 48 hours was chosen based on

Cox regression guided the selection of candidate factors and vari-

the observation that critically ill patients received a high number of

ables with P-values of .1 were included for stepwise AIC variable

transfusions even in the absence of major bleeding.

selection.
Statistical analysis was performed using JMP (software version

2.2 | Outcomes and statistical analysis

14.0.0) and R statistical software (software version 4.0.0). The package TWANG (version 1.6) was employed for calculation of the PS
weights.16

Categorical variables are reported with counts (percentages).
Numerical variables are reported as either mean (sd = standard deviation), if normal or approximately normal variables, or
median (interquartile range [IQR]) for all other numerical variables. To assess normality of numerical variables, the Lilliefors-

3 | R E S U LT S
3.1 | Study population and baseline characteristics

Kolmogorov-Smirnov test was used together with the variable
boxplot. Comparisons by groups were performed using chi-square

Between March 13, 2020, and May 5, 2020, 3717 adults tested

tests (or Fisher tests if cell count <5). ANOVA tests were used

positive for SARS-CoV-2 in our healthcare system. Of these, 3480

for comparison of means for normally distributed variables.

tested positive on the first 3 days of a hospital admission. The major-

Kruskal-Wallis tests were applied for comparison of the distri-

ity (2838 [81.5%]) were treated in a non-ICU setting, whereas the

bution of non-normal numerical variables. Pairwise comparisons

remainder (642 [18.5%]) required mechanical ventilation and were

between the groups were performed utilizing either Tukey's ad-

included in the ICU group. Figure 1 provides an outline of the study

justment for approximately normal distributions or Dunn's test for

population. The mean age of the overall population was 64.5 years

the comparison for non-normal variables with Hommel's adjust-

(17.0) and the sex distribution was balanced with 51.5% females and

ment. All P-values were 2-sided and a P < .05 was considered to

48.5% males. Baseline characteristics of the overall study population

indicate statistical significance. Adjustment for multiple testing is

are presented in Table 1.

presented in Table 1 using the method of false discovery rate of
15

Benjamini, Hochberg and Yekutieli.

Most patients received pAC (2121 [60.9%]) and almost one
third received tAC courses of 3 days or more (998 [28.7%]). Only

Multivariate Cox regression was used to evaluate the survival

361 (10.4%) did not receive any dose of anticoagulant. Of the 3119

time of COVID-19 patients compared between those who re-

patients who received any dose of AC, 554 (17.8%) switched be-

ceived tAC, Pac, and no AC. Time zero was the time of admission

tween different anticoagulant agents of the same dose intensity.

and patients were right-censored at the time of discharge or at the

The most common primary anticoagulant in the pAC group was

end of the study period if they remained hospitalized. Propensity

enoxaparin (1156 [54.5%]), followed by UFH (699 [33.0%]) and

score (PS) weights were used as a summary adjustment variable to

fondaparinux (7 [0.3%]). Patients who received less than 3 days

address the issue of possible bias introduced by the retrospective

of tAC (259) were included in the pAC group. Agents used for tAC

nature of the study. This approach was preferred to PS matching

had a similar distribution: enoxaparin (424 [42.5%]), UFH (295

to preserve the sample size. The PS was calculated using a logistic

[29.6%]), and fondaparinux (6 [0.6%]). Remaining tAC patients (273

regression model with categorical AC group as dependent variable

[10.4%]) received primarily oral agents: apixaban (183 [18.3%]),

and it was adjusted for the following covariables: age (years), sex,

warfarin (42 [4.2%]), rivaroxaban (46 [4.6%]), and dabigatran (2

race with 4 levels (Caucasian, African-American, Asian, Other),

[0.2%]). The median time from admission to initiation of tAC was

body mass index (BMI) with 4 levels (<18.5, 18.5-30, 30-40,

2 days (IQR 1-6 days) and the median duration of tAC was 8 days

>40 kg/m2), as well as comorbid conditions (hypertension, hyper-

(IQR 5-12 days).

lipidemia, coronary artery disease, peripheral artery disease, heart

Analysis of demographics and medical history (Table 1) revealed

failure, cerebral vascular attack/transient ischemic attack, atrial

that the tAC group was comprised, on average, of an older popula-

fibrillation, chronic kidney disease grade 3 or above, hemodialysis

tion (68.2 years [14.6] vs 64.4 [16.9] in the pAC and 55.0 [21.7] in the

dependence, history of malignancy, history of venous thrombo-

no AC groups), with a higher frequency of common comorbid con-

embolism, immunocompromised status, connective tissue disease,

ditions. Rates of therapeutic interventions are presented in Table 1.

4
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TA B L E 1

Baseline characteristics and comorbid conditions in overall COVID-19 study population
All patients
(n = 3480)

No AC (n = 361)

pAC (n = 2121)

tAC (n = 998)

P-value adj.
P-value

Age in years

64.5 (±17.0)

55.0 (±21.7)

64.4 (±16.9)

68.2 (±14.6)

<.001a
<.001

Female

1796 (51.5%)

207 (57.3%)

1138 (53.7%)

448 (44.9%)

<.001

Male

1687 (48.5%)

154 (42.7%)

550 (55.1%)

<.001

983 (46.3%0

Race
African-American

1814 (52.1%)

197 (54.6%)

1149 (54.2%)

468 (46.9%)

Caucasian

1413 (40.6%)

149 (41.3%)

827 (39.0%)

437 (43.8%)

<.001

69 (2.0%)

2 (0.6%)

45 (2.1%)

22 (2.2%)

<.001

Asian
Other

184 (5.3%)

BMIb (kg/m2)b

30.4 (12.9, 103.9)

13 (3.6%)
30.5 (15.4, 66.7)

100 (4.7%)
30.4 (12.9, 103.9)

71 (7.1%)
30.4 (14.5, 73.3)

.285
.285

BMI (kg/m2)b
81 (2.4%)

<18.5

7 (2.1%)

55 (2.7%)

19 (1.9%)

920 (44.9%)

447 (45.5%)

.279

136 (40.1%)

774 (37.8%)

350 (35.6%)

.285

42 (12.4%)

299 (14.6%)

166 (16.9%)

1812 (52.1%)

120 (33.2%)

1086 (51.2%)

606 (60.7%)

<.001
<.001

1008 (29.0%)

67 (18.6%)

595 (28.1%)

346 (34.7%)

<.001
<.001

18.5-30

1521 (45.2%)

154 (45.4%)

30-40

1260 (37.4%)
507 (15.0%)

Hypertension
Diabetes

≥40

Coronary artery disease

425 (12.2%)

29 (8.0%)

231 (10.9%)

165 (16.5%)

<.001
<.001

Heart failure

272 (7.8%)

25 (6.9%)

134 (6.3%)

113 (11.3%)

<.001
<.001

Atrial fibrillation

195 (5.6%)

18 (5.0%)

62 (2.9%)

115 (11.5%)

<.001
<.001

Ischemic stroke or TIA

312 (9.0%)

23 (6.4%)

171 (8.1%)

118 (11.8%)

<.001
<.001

CKD grade 3 and above

203 (5.8%)

15 (4.2%)

105 (5.0%)

83 (8.3%)

<.001
<.001

97 (2.8%)

10 (2.8%)

50 (2.4%)

37 (3.7%)

.016
.019

History of VTE

203 (5.8%)

15 (4.2%)

75 (3.5%)

113 (11.3%)

<.001
<.001

Chronic lung disease

760 (21.8%)

78 (21.6%)

433 (20.4%)

249 (24.9%)

.017
.019

History of malignancy

278 (8.0%)

19 (5.3%)

157 (7.4%)

102 (10.2%)

.003
.004

1040 (38.4%)

95 (33.6%)

622 (37.8%)

323 (41.4%)

-

Dialysis dependent

Ever smokerc
D-dimer > 3000 ng/mL

d

Mechanical ventilation
No mechanical ventilation
AKI requiring dialysis

831 (35.2%)

15 (14.3%)

281 (20.7%)

535 (59.6%)

642 (18.5%)

18 (5.0%)

207 (9.8%)

417 (41.8%)

2838 (81.5%)

343 (95.0%)

1914 (90.2%)

581 (58.2%)

67 (3.2%)

139 (13.9%)

214 (6.2%)

8 (2.2%)

No new dialysis requirement

3266 (93.8%)

353 (97.8%)

2054 (96.8%)

859 (86.1%)

Corticosteroid treatment

1825 (52.4%)

64 (17.7%)

1003 (47.3%)

758 (76.0%)

No corticosteroid treatment

1655 (47.6%)

297 (82.3%)

1118 (52.7%)

240 (24.0%)

<.001
<.001
<.001

HQ and Azithromycin

(Continues)
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(Continued)
All patients
(n = 3480)

None

592 (17.0%)

No AC (n = 361)
171 (47.4%)

pAC (n = 2121)

tAC (n = 998)

332 (15.7%)

89 (8.9%)

HQ only

356 (10.2%)

17 (4.7%)

224 (10.6%)

115 (11.5%)

Azithromycin only

332 (9.6%)

63 (17.5%)

232 (10.9%)

37 (3.7%)

2200 (63.2%)

110 (60.5%)

1333(62.8%)

757 (75.9%)

HQ and Azithromycin

P-value adj.
P-value

<.001

Note: Age is presented as mean (standard deviation). BMI is presented as median (range). Other numbers represent n (%).The adjusted P-value uses
Benjamini, Hochberg and Yekutieli 20,21 method that controls the false discovery rate.
Bold values indicates P-value < .05.
Abbreviations: AC, anticoagulation; AKI, acute kidney injury; BMI, body mass index; CKD, chronic kidney disease; HQ, hydroxychloroquine; pAC,
prophylactic anticoagulation; tAC, therapeutic anticoagulation; TIA, transient ischemic attack; VTE, venous thromboembolism.
a

All means significantly different (P < .001) using post hoc Tukey's HSD.

b
c

Data for BMI available for N = 3369.

Data for smoker status available for N = 2710.

d

Data for D-dimer available for N = 2363.

3.2 | Anticoagulation and in-hospital mortality

at 25 days postadmission were seen in patients receiving tAC compared to those receiving only pAC in both the ICU (56.3% vs 22.5%)

In-hospital mortality among the groups was statistically differ-

and non-ICU (78.5% vs 65.7%) populations. Baseline characteristics

ent (11.4% for no AC, 10.8% for pAC and 23.6% for tAC; P < .001).

of these two populations are presented in Tables S1 and S2.

Median survival times were 25 days for pAC and 30 days for tAC.

A preliminary PS-weighted univariate Cox regression identified

The median survival time was not reached in the no AC group. PS-

the following potential predictors of death (significant at the 0.1

weighted Kaplan-Meier curves were statistically different for the

level): age, BMI, race, categorical AC group, corticosteroid treatment,

tAC group compared to the pAC and no AC groups (Figure 2). At

ICU stay, acute kidney injury (AKI) requiring dialysis, hypertension,

hospital day 25, the survival probability in the tAC group was visually

coronary artery disease, heart failure, and combination of hydroxy-

higher than in the pAC group (57.5% vs 50.7%). In the no AC group,

chloroquine (HQ) and azithromycin. D-dimer values and smoking

the last event occurred at 11 days at which time the survival prob-

status were not included in the final model due to missing values

ability was 61.0%.

and to preserve sample size. The final multivariate Cox regression

In the ICU group, 310 (48.3%) patients died during their hospital

model is shown in Table 2. Independent predictors of mortality were

stay (median survival time 22 days) compared to 196 (6.9%) in the

age (P < .001, hazard ratio [HR] 1.6 per 10-year increase [95% con-

non-ICU population (median survival time not reached). PS-weighted

fidence interval {CI} 1.4-1.8]), ICU stay (P < .001, HR 5.2 [95% CI

Kaplan-Meier curves stratified by disease severity are shown in sup-

3.5-7.8]), and poor nutritional status defined as BMI < 18.5 (P = .001,

plemental Figure S1 panels A and B. Different survival probabilities

HR 3.0 [95% CI 1.5-6.0]); AKI requiring dialysis was linked to a poor

F I G U R E 1 Outline of study population.
AC, anticoagulation; pAC, prophylactic
anticoagulation; tAC, therapeutic
anticoagulation

6
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F I G U R E 2 Propensity score-weighted
Kaplan-Meier survival curves by AC
dose in overall study population. AC,
anticoagulation; pAC, prophylactic
anticoagulation; tAC, therapeutic
anticoagulation. Numbers at risk represent
estimates obtained through PS weighting
and not the actual number of cases; this
approach ensures that patients who are
not included will account for their share
of the population and adjust the survival
probability for possible sources of bias

Hazard ratio
Age (years)

1.6

a

Confidence
interval

Significance

1.4-1.8

<.001

TA B L E 2 Propensity score-weighted
multivariate Cox proportional hazards
model

BMI (kg/m2)b
<18.5 kg/m2

3.0

1.5-6.0

.001

30-40 kg/m2

0.8

0.6-1.1

.214

≥40 kg/m

2

ICU stay

1.1

0.7-1.6

.779

5.2

3.5-7.8

<.001

Prophylactic anticoagulationc

0.35

0.22-0.54

<.001

Therapeutic anticoagulationc

0.14

0.08-0.23

<.001

AKI requiring dialysis

1.3

0.96-1.8

.095

HQ and Azithromycin
HQ

0.7

0.4-1.2

.29

Azithromycin

1.4

0.6-3.1

.41

HQ and Azithromycin

0.7

0.4-1.2

.27

Abbreviations: AKI, acute kidney injury; Azithro, azithromycin; HQ, hydroxychloroquine; ICU,
intensive care unit.
a

Per 10-year increase

b
c

Reference is BMI between 18.5-30 kg/m2

Reference is no AC

prognosis (HR 1.3 [95% CI 0.96-1.8]), but did not reach significance

no AC, pAC was associated with a 65% decrease in the risk of death

(P = .095). AC was associated with a reduced risk of death in the

(HR 0.35 [95% CI 0.22-0.54]) and tAC with 86% decrease (HR 0.14

multivariate model. The effect was dose-dependent: compared to

[95% CI 0.05-0.23]). In both the raw and PS-weighted multivariate

|
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analyses, corticosteroids did not significantly impact mortality risk.

in critically ill patients; and 3) major bleeding events occurred more

The effect of tAC prior to admission for pre-existing indications

frequently in patients receiving tAC.

(VTE, atrial fibrillation etc) and that of increasing experience with

Our study population was derived from a large US cohort (3480

COVID-19 (the week of diagnosis) did not impact outcomes in the

subjects), of which nearly one fifth required care in an intensive care

model.

setting. Most (90%) received AC, with nearly two thirds receiving
prophylactic doses and one third receiving therapeutic doses. For

3.3 | Complications of anticoagulant treatment

the remainder of the population, AC was likely withheld because of
active or potential bleeding complications, low baseline hemoglobin
or platelet count, and individual physician practice patterns. The pre-

Major bleeding events defined by composite criteria occurred in 147

cise indication for the initiation of tAC was not available for analysis,

subjects: 81 (8.1%) patients treated with tAC compared to 20 (5.5%)

but certain observations suggest that COVID-19-associated hyper-

among those who received no AC and 46 (2.3%) in those who re-

coagulability was a frequent indication: (a) the number of patients

ceived pAC (Table 3). Patients requiring mechanical ventilation had

who continued oral anticoagulant therapy inpatient was relatively

a markedly higher rate of bleeding (80 [12.5%] vs 67 [2.4%]). When

small (25.7%) corresponding to a low prevalence of pre-existing co-

comparing the frequency of intracranial bleeding, 13 patients (1.3%)

morbid conditions requiring AC; (b) the true inpatient incidence of

had an event in the tAC group, compared to 4 (1.11%) in the no AC

VTE was unknown due to limitation of diagnostic imaging in an ef-

and 10 (0.5%) in the pAC groups (P = .028).

fort to decrease exposure and, as such, these were less likely to con-

The presence of severe thrombocytopenia (platelet count

stitute AC indications; (c) among deceased patients in our institution,

<50.000/µL on at least two occasions 24 hours apart) was re-

COVID-19-associated hypercoagulability was the sole indication in

ported in 34 patients (3.4%) in the tAC group, 10 (2.8%) in the no

55% of subjects12; and (d) institutional guidelines recommended use

AC and 27 (1.3%) in the pAC groups (P < .001). Eleven cases (1.1%)

of tAC in a sicker patient population.

who received tAC had confirmed heparin-induced thrombocytope-

A propensity score-weighted multivariate proportional hazards

nia (HIT), whereas only 1 (0.05%) patient treated with pAC devel-

model found that AC was associated with a decreased risk of mor-

oped HIT. Half the patients diagnosed with HIT (6/12) had severe

tality and the effect appeared to be dose-dependent, with prophy-

thrombocytopenia.

lactic doses conferring a 65% decrease in risk (HR of 0.35 [95% CI
0.22-0.54]) and therapeutic doses an 86% decrease (HR of 0.14 [95%
CI 0.08-0.23]) compared to patients who did not receive AC. The

4 | D I S CU S S I O N

sizeable effect of pAC on mortality in COVID-19 was surprising as
studies of pAC in the non-surgical acutely ill population have gen-

The biological basis for the potential benefit of anticoagulation in

erally failed to demonstrate a survival benefit. 21 The benefit of AC,

COVID-19 is derived from reports of hypercoagulability and en-

although more prominent in the ICU population, was evident in all

dothelial dysfunction2,6,17-19 with resulting formation of micro- and

hospitalized patients in our cohort. In line with institutional recom-

macrothrombi.8,9,20 Ours is among the first and the largest studies to

mendations, patients with severe organ failure and those with evi-

evaluate the effect of AC on survival in COVID-19. Our main findings

dence of coagulation abnormalities (high D-dimer) were most likely

are as follows: 1) both prophylactic and therapeutic AC were asso-

to receive tAC, but even after adjusting for multiple factors (includ-

ciated with decreased mortality in COVID-19; 2) patients receiving

ing critical illness), the higher benefit of tAC remained evident. Due

therapeutic doses had higher survival probability compared to those

to a large number of missing D-dimer values and recognizing that

receiving prophylactic doses, and the greatest effect was observed

available measurements would likely have been obtained in more

TA B L E 3

Complications of AC in the overall COVID-19 population
All patients (n = 3480)

Major bleeding
No major bleeding

147 (4.2%)

20 (5.5%)

3333 (95.8%)

341 (94.5%)

≥5 units PRBC in 48 h

70 (2.0%)

<5 units PRBC in 48 h

3410 (98.0%)

Intracranial hemorrhage
No intracranial hemorrhage
Severe thrombocytopenia
No severe thrombocytopenia

No AC (n = 361)

27 (0.8%)
3453 (99.2%)
71 (0.2%)
3406 (97.8%)

9 (2.5%)
352 (97.5%)
4 (1.1%)
357 (98.9%)
10 (2.8%)
349 (97.2%)

pAC (n = 2121)
46 (2.2%)
2075 (97.8%)
18 (0.9%)
2103 (99.1%)
10 (0.5%)
2111 (99.5%)
27 (1.3%)
2093 (98.7%)

tAC (n = 998)
81 (8.1%)

Significance
<.001

917 (91.9%)
43 (4.3%)

<.001

955 (95.7%)
13 (1.3%)

.028

985 (98.7%)
34 (3.4%)

<.001

964 (96.6%)

Abbreviations: AC, anticoagulation; AKI, acute kidney injury; HQ, hydroxychloroquine; pAC, prophylactic anticoagulation; tAC, therapeutic
anticoagulation.
Bold values indicates P-value < .05.
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severe disease and, hence, would not satisfy the missing at random

ill patients, especially in the tAC vs pAC groups (31.7% vs 20.5%;

assumption, we chose to forego analysis of the interaction between

P = .07).14 While the benefit of tAC came at the cost of more bleed-

D-dimer level and AC in an effort to avoid confounding.

ing, the rate of intracranial bleed as evidenced on cranial imaging

Our results supplement those of recent investigations focused

was similar between the tAC and no AC groups (1.3% vs 1.1%). If

on the use of AC in COVID-19 conducted on a large cohort of hos-

the considerable survival advantage of tAC is replicated in prospec-

pitalized patients in the Northeastern United States. The first study

tive studies, it may be reasonable to accept a higher risk of non-dis-

by Paranjpe et al found similar in-hospital mortality rates between

abling bleeding or transfusion requirement given the potentially

patients treated with tAC and those who were not (22.5% vs 22.8%),

fatal course of the disease and lack of other proven therapeutic in-

a longer median survival time in the tAC group (21 days vs 14 days),

terventions. Several randomized clinical trials (eg, NCT04372589,

and an association between tAC duration and reduced risk of death

NCT04409834, NCT04406389, and NCT04359277) are ongoing

(HR, 0.86 per day [95% CI 0.82-0.89]).13 Subsequently, Trinh et al re-

to test whether higher dose AC improves outcomes among patient

ported a 79% decrease in the risk of death in patients treated with

with COVID-19.

at least 5 days of tAC compared to pAC (HR, 0.209 [95% CI 0.10.46]) in critically ill patients belonging to the same cohort and.14
Most recently, Nadkarni et al expanded the existing cohort to nearly

4.1 | Limitations

4400 subjects and specifically investigated the impact of tAC and
pAC compared to patients who did not receive AC. In a multivariate

This retrospective, observational study has several important limi-

model adjusting for critical illness, the authors found a similar reduc-

tations. By design, the study can only report associations, cannot

tion in in-hospital mortality with both tAC (HR, 0.53 [95% CI 0.45-

investigate causality, and is susceptible to multiple sources of bias

0.62]) and pAC (HR, 0.50 [95% CI 0.45-0.57]). In a direct comparison

such as indication bias and hidden confounders. We attempted to

of tAC and pAC initiated in the first 48 hours of hospitalization, the

control for these using a PS-weighted multivariate model. A high

risk was lower with higher doses but did not reach significance (HR,

proportion of missing data as can be expected with automatically

0.86 [95% CI 0.73-1.02]).

extracted information from electronic medical records was a par-

Overall, AC had a consistently demonstrated survival bene-

ticular challenge in our cohort and made it difficult to investigate

fit, but the effect size was highly variable owing to differences in

the value of laboratory coagulation studies (chiefly D-dimer) that

the definition of AC duration, dosing, and statistical methods em-

have been identified as candidate measurements to identify pa-

ployed for adjustment. Nadkarni et al study found a more modest

tients to most likely benefit from AC. Imputation of missing data

risk reduction (50% compared to 86% in our analysis), which may

could not be used because of violation of the missing at random

be explained by use of competing risk analysis and the exclusion of

assumption and difficulty in reconciling imputation with the PS

patients who received both pAC and tAC throughout their hospital

weighting method. One potential limitation was the inclusion of

stays. We believe the latter choice, intended to simplify exposures,

patients with less than three days of tAC in the pAC group. The

may have biased results as subjects whose clinical status worsened

reasons for shorter duration of tAC (bleeding, discharge, death)

throughout their hospital stay (and, thus, for whom escalating AC

may have skewed results slightly, but their number was relatively

dose may have been reasonable) would be lost to the analysis; fol-

small and analyzing these patients in the tAC group would have

lowing the same rationale, this same group may have included a high

introduced its own type of bias as others have pointed out that AC

number of critically ill patients. Another conspicuous aspect of the

is infrequently truly therapeutic in this timeframe.14 More granu-

Nadkarni et al study is the large number of hospitalized patients not

lar analyses to compare the benefit of heparin and non-heparin

receiving any AC (1530 [35%]) which represents a departure from

anticoagulants or to identify the precise cause of death were not

current guidelines on venous thromboembolic prophylaxis in hospi-

possible. Another source of bias is heterogeneity resulting from

talized patients.

the creation of institutional recommendations pertaining to AC

Due to conflicting results and significant bias in available anal-

throughout the study period as new data emerged about the ben-

yses, the question of optimal AC dosing remains unanswered. The

efits of AC. An example is the higher attrition rate of patients who

importance of dosing is highlighted by increased major bleeding in

did not receive AC or who received pAC, which may lead to bias in

the tAC group (as high as 8% of patients) according to definitions

comparisons; these represent a mixed population who were either

set in our study, which were largely more conservative compared

admitted prior to the institutional recommendation to use tAC or

to those of others. Surprisingly, a greater number of patients who

had less severe disease and were discharged early. Similarly, the

did not receive AC (5.5%) experienced bleeding compared to 2.2%

introduction of these recommendations at our institution likely

of those treated with pAC. This suggests that AC was withheld for

coincided with an increase in our clinical experience in the man-

those with active bleeding or an increased propensity to bleed.

agement of COVID-19, and confounding may influence our obser-

Frequencies in our cohort are higher, but comparable to those re-

vations. We did attempt to control for the latter by introducing

ported by Nadkarni et al (3% and 1.7% for those receiving tAC and

a time variable representing the week of the pandemic in which

pAC respectively, compared to 1.9% in the no AC group).11 Trinh

patients were diagnosed into the multivariate models, but this did

et al reported markedly higher rates of bleeding events in critically

not impact outcomes.
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